Neuraxis Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neuraxis Inc 's ROA in the second quarter of 2026?
Neuraxis Inc recorded a cumulative net loss of $-8 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -99.33%.

However, within the Healthcare sector 739 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4279, from total ROA ranking in the first quarter of 2026 at 5065.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	41.03 %	188.66 %	34.61 %	583.24 %	169.17 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-7	-8	-8	-7
Return On Assets (TTM)	-99.33 %	-103.99 %	-139.93 %	-146.04 %	-182.49 %
NRXS's Total Ranking	# 4279	# 5065	# 4508	# 4654	# 4821
Total Assets (TTM) in million	10	9	6	6	7
Seq. Total Assets Change	14.3 %	36.57 %	10.87 %	-18.51 %	133.94 %
Seq. Net Income Change	-	-	-	-	-

NRXS's 5 Years Annual ROA >> Back to NRXS Management Effectiveness >> Compare NRXS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 172
Sector	# 740
Overall	# 4222

Return On Assets Statistics
High	Average	Low
-99.33 %	-518.13 %	-1377.88 %
(Jun 30 2026)		(Mar 31 2024)

News about Neuraxis Inc Return on Assets ROA

NeurAxis Inc.: Bridging Challenges and Triumphs in Neuromodulation Therapy

In the rapidly evolving healthcare sector, NeurAxis Inc. (NYSE American: NRXS) is a notable player, focusing on the commercialization of neuromodulation therapies aimed at alleviating chronic ailments in both children and adults. A recent letter from CEO Brian Carrico to shareholders provided insights into the company’s trajectory, including achievements in 2024 and a vision for the forthcoming year. However, the company is navigating a landscape marked by substantial financial challenges.Financial Performance and Losses:During the 12 months leading up to the third quarter of 2024, NeurAxis recorded a cumulative net loss of $14 million, which translates to a staggering negative return on assets (ROA) of -1261.94%. This figure starkly contrasts with 930 other companies within the healthcare sector, which posted more favorable ROA metrics. Despite these financial setbacks, NeurAxis has managed to slightly improve its ranking in ROA from 4581 in the previous quarter to 4346, indicating small, albeit notable progress in the context of its operational struggles.

NeurAxis Expands Access to Percutaneous Electrical Nerve Field Stimulation with New Coverage Agreements in Pennsylvania and North Dakota

NeurAxis Expands Access to Percutaneous Electrical Nerve Field Stimulation with New Coverage Agreements in Pennsylvania and North DakotaCARMEL, Ind. — NeurAxis, Inc. (NYSE American: NRXS), a pioneering medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, has made significant strides in expanding access to its innovative treatment, Percutaneous Electrical Nerve Field Stimulation (PENFS). Effective October 1, 2024, Capital Blue Cross will provide medical policy coverage for PENFS to its members in a 21-county region across Central Pennsylvania and the Lehigh Valley. This addition marks a crucial milestone for NeurAxis, as it broadens the availability of this treatment option and underscores the company’s commitment to improving patient outcomes.Earlier this year, on April 23, 2024, NeurAxis celebrated another key achievement with the announcement of medical policy coverage for PENFS in North Dakota. The coverage is facilitated through a partnership with a Blue Cross Blue Shield licensee, which represents the largest health care provider in the state, insuring over 310,000 individuals. This policy is set to take effect on May 6, 2024, further enhancing the reach of NeurAxis’s novel therapeutic interventions.

Financial Statements
Neuraxis Inc 's Assets	$ 10 million	NRXS's Balance sheet
Neuraxis Inc 's Income	$ -2 million	Quarterly NRXS's Income Statement
NRXS's Income by Division		See NRXS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	34.61 %	983.14 %	-	-	-
Total Assets in million	6	5	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-8	-15	0	0
Annual Return On Assets	-121.81 %	-173.23 %	-3329.96 %	-	-

NRXS's 5 Years Annual ROA >> Back to NRXS Management Effectiveness >> Compare NRXS ROA to its Competitors

More Return On Assets Ratios
NRXS's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NRXS's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NRXS's Competitors
Subscribers only: Roa for Neuraxis Inc 's Suppliers
Subscribers only: Return On Assets for NRXS's Customers

You may also want to know
NRXS's Roi	NRXS's Inventory Turnover Ratio	NRXS's Growth Rates	NRXS's Dividend Comparisons
	NRXS's Profitability Ratios	NRXS's Asset Turnover Ratio	NRXS's Dividend Growth
NRXS's Roe	NRXS's Valuation Ratios	NRXS's Financial Strength Ratios	NRXS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:26:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.